Skip to main content
Journal cover image

Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.

Publication ,  Journal Article
Huang, L-W; Bacon, W; Cirrincione, C; Peterson, B; Long, G; Rizzieri, D; Sullivan, KM; Corbet, K; Horwitz, M; Chao, N; Gasparetto, C; Tuchman, SA
Published in: Hematol Oncol
December 2017

We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT. Our null hypothesis was that the PFS hazard ratio (HR) for a 5-year increase in age was ≥1.05; the alternative (non-inferiority) hypothesis was that the HR was ≤1. The observed HR was 0.94 (95% confidence interval [CI] 0.86-1.03); since the CI upper bound was <1.05, we reject the null hypothesis and conclude that PFS in older patients was at least as good as in younger patients. We cannot reject an analogous null hypothesis for overall survival (HR 1.06 [95% CI 0.94-1.19]), since the CI upper bound >1.05. Toxicity was similar across ages and transplant-related mortality was minimal. 28% of subjects <65 versus 45% of those ≥65 received maintenance therapy. In summary, ASCT prolongs PFS equally well in older vs. younger adults. Although we cannot exclude maintenance as a confounder, these data support ASCT for fit seniors with MM.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Hematol Oncol

DOI

EISSN

1099-1069

Publication Date

December 2017

Volume

35

Issue

4

Start / End Page

752 / 759

Location

England

Related Subject Headings

  • Transplantation, Autologous
  • Transplantation Conditioning
  • Survival Rate
  • Retrospective Studies
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Huang, L.-W., Bacon, W., Cirrincione, C., Peterson, B., Long, G., Rizzieri, D., … Tuchman, S. A. (2017). Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematol Oncol, 35(4), 752–759. https://doi.org/10.1002/hon.2379
Huang, Li-Wen, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn Long, David Rizzieri, Keith M. Sullivan, et al. “Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.Hematol Oncol 35, no. 4 (December 2017): 752–59. https://doi.org/10.1002/hon.2379.
Huang L-W, Bacon W, Cirrincione C, Peterson B, Long G, Rizzieri D, et al. Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematol Oncol. 2017 Dec;35(4):752–9.
Huang, Li-Wen, et al. “Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.Hematol Oncol, vol. 35, no. 4, Dec. 2017, pp. 752–59. Pubmed, doi:10.1002/hon.2379.
Huang L-W, Bacon W, Cirrincione C, Peterson B, Long G, Rizzieri D, Sullivan KM, Corbet K, Horwitz M, Chao N, Gasparetto C, Tuchman SA. Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematol Oncol. 2017 Dec;35(4):752–759.
Journal cover image

Published In

Hematol Oncol

DOI

EISSN

1099-1069

Publication Date

December 2017

Volume

35

Issue

4

Start / End Page

752 / 759

Location

England

Related Subject Headings

  • Transplantation, Autologous
  • Transplantation Conditioning
  • Survival Rate
  • Retrospective Studies
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation